Država: Malezija
Jezik: angleščina
Source: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
BRINZOLAMIDE; TIMOLOL
NOVARTIS CORPORATION (MALAYSIA) SDN. BHD.
BRINZOLAMIDE; TIMOLOL
5ml mL
S.A. ALCON-COUVREUR N.V.
_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP)_ _ _ AZARGA _® _ Eye Drops _Brinzolamide/ Timolol (10mg/ml, 5mg/ml)_ _ _ 1 WHAT IS IN THIS LEAFLET 1. What Azarga is used for 2. How Azarga works 3. Before you use Azarga 4. How to use Azarga 5. While you are using Azarga 6. Side effects of Azarga 7. Storage and disposal of Azarga 8. Product Description 9. Manufacturer 10. Product Registration Holder 11. Date of revision WHAT AZARGA IS USED FOR Azarga is used to treat high pressure in the eyes, also called glaucoma or ocular hypertension, in adult patients and in whom high pressure in the eyes cannot be controlled effectively by one medicine alone. HOW AZARGA WORKS Azarga contains two active substances: brinzolamide and timolol which work together to reduce pressure within the eye. BEFORE YOU USE AZARGA _When you must not use it _ Do not use Azarga: _ _ If you are allergic to brinzolamide, timolol, or any of the other ingredients of this medicine. If you are allergic to medicines called sulphonamides. Examples include medicines used to treat diabetes, infections and also diuretics (water tablets). Azarga may cause allergic reaction. If you have now or have had in the past respiratory problems such as asthma, severe long lasting obstructive bronchitis (severe lung condition which may cause wheezing, difficulty in breathing and/or long standing cough) or other types of breathing problems. If you have severe hay fever. If you have a slow heart beat, heart failure or disorders of heart rhythm (irregular heartbeats). If you have too much acidity in your blood (a condition called hyperchloraemic acidosis). If you have severe kidney problems. _ _ _Pregnancy and breast-feeding _ You should not use Azarga if you are pregnant or might get pregnant, unless your doctor considers it necessary. Talk to your doctor before you use Azarga. Do not use Azarga if you are breast- feeding. Timolol may get into your milk. Ask your doctor for advice before taking any medicine during breastfeeding. _Before you Preberite celoten dokument
Novartis Page 2 CDS v4.1 26-May-2022 Azarga ® 2 1. NAME OF THE MEDICINAL PRODUCT AZARGA 10 mg/ml + 5 mg/ml eye drops, suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of suspension contains 10 mg brinzolamide and 5 mg timolol (as timolol maleate). Excipient with known effect One ml of suspension contains 0.10 mg benzalkonium chloride. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Eye drops, suspension (eye drops) White to off-white uniform suspension, pH 7.2 (approximately). 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Decrease of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Use in adults, including the elderly _ The dose is one drop of AZARGA in the conjunctival sac of the affected eye(s) twice daily. When using nasolacrimal occlusion or closing the eyelids, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity (see section 4.4). If a dose is missed, treatment should be continued with the next dose as planned. The dose should not exceed one drop in the affected eye (s) twice daily. When substituting another ophthalmic antiglaucoma medicinal product with AZARGA, the other medicinal product should be discontinued and AZARGA should be started the following day. _Special populations _ _Paediatric population _ The safety and efficacy of AZARGA in children and adolescents aged 0 to 18 years have not yet been established. No data are available. Novartis Page 3 CDS v4.1 26-May-2022 Azarga ® 3 _Hepatic and renal impairment _ No studies have been conducted with AZARGA eye drops in patients with hepatic or renal impairment. No dosage adjustment is necessary in patients with hepatic impairment or in patients with mild to moderate renal impairment. AZARGA has not been studied in patients with severe renal impairment (creatinine cleara Preberite celoten dokument